References
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 131: 749–757
- Ataergin S, Arpaci F, Kaya A, Turker K, Gunhan O. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol 2006; 81: 987–988
- Blade J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000; 39: 843–847
- Petrucci M T, Martini V, Levi A, Gallucci C, Palumbo G, Del Bianco P, et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma 2007; 48: 180–182
- Finnegan D P, Kettle P, Drake M, Matthews C, Alexander H D, Popat R, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006; 47: 1670–1673
- Grassinger J, Sudhoff T, Andressen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006; 85: 132–133
- Jaskiewicz A D, Herrington J D, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005; 25: 1820–1825
- Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutierrez B, Blade J, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665–667
- Durie B GM, Salmon S E. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–854
- Greipp P R, San Miguel J, Durie B GM, Crowley J J, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420
- Oken M M, Creech R H, Tormey D C, Horton J, Davis T E, McFadden E T, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
- Anderson K C. Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Semin Hematol 2005; 4: S3–S8
- Richardson P, Schlossman R I, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory derivative of thalidomide CC5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067
- Muller G, Chen R, Huang S Y, Corral L G, Wong L M, Patterson R T, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-production. Bioorg Med Chem Lett 1999; 9: 1625–1630
- Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530